30 Day Trial

Alphatec Spine Posts 3Q15 Revenue

Share:

Alphatec Spine posted 3Q15 revenue of US $42.9MM, -15.7% as reported, -10.4% in constant currency, and YTD 2015 revenue of $138.2MM, -9.8% / -3.7% CC.

For 3Q15, geographic breakdown of revenue is U.S. $27.3MM, -21.3%; ex-U.S. $15.6MM, +13.2%.

The company affirmed that its Arsenal CBX™ Cortical Bone Fixation system, used in >50 patients during limited launch, will enter full commercial release in 2015, and noted that Arsenal Deformity and lateral development programs are on-track for introduction in 1Q16

The outsourcing of manufacturing initiative should complete in January 2016. Alphatec announced a partnership with UPS for distribution of implant and instrument sets; rollout is underway.

Finally, the company expects to gain a minimum of $3MM in sales within new large metropolitan U.S. markets during 4Q15. For full-year 2015, Alphatec estimates revenue of $188.7MM. 

Source: Alphatec Spine, Inc.